BACKGROUND: Primary central nervous system posttransplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication after solid organ transplantation (SOT). With increasing rates of SOT, PCNS-PTLD incidence is increasing. OBJECTIVE: To describe the characteristics of PCNS-PTLD patients requiring neurosurgical intervention. METHODS: From 2000 to 2011, 10 patients with prior SOT underwent biopsy for evaluation of brain lesions and were diagnosed with PCNS-PTLD. Data collected included imaging characteristics, pathology, treatments administered, and survival outcomes. RESULTS: All patients had kidney transplantation, and 3 had concurrent pancreas transplantation. Median age at diagnosis was 49 years, with a median of 4.5 years from SOT to diagnosis (range, 1.8-11.4 years). Presenting symptoms most often included focal neurological deficits (n = 6), although several patients had nonspecific symptoms of headache and altered mental status. Brain lesions were generally multiple (n = 7), supratentorial (n = 8), and lobar or periventricular in distribution with ring enhancement. Diagnosis was established by stereotactic (n = 4) and open surgical (n = 6) biopsy. Treatments most frequently administered included reduction of immunosuppression (n = 10), dexamethasone (n = 10), rituximab (n = 8), high-dose methotrexate (n = 3), and whole-brain radiotherapy (n = 6). Six patients remain alive without PCNS-PTLD relapse, including 4 patients who have sustained remissions beyond 2 years from diagnosis of PCNS-PTLD. Of 4 observed deaths, 1 was related to progressive PCNS-PTLD. CONCLUSION: PCNS-PTLD must be considered in the differential diagnosis of any patient with prior SOT presenting with an intracranial lesion. Histological diagnosis with brain biopsy is imperative, given the risk for opportunistic infections that may have similar imaging findings and presentation. Prognosis is variable, although long-term survival has been reported.
BACKGROUND:Primary central nervous system posttransplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication after solid organ transplantation (SOT). With increasing rates of SOT, PCNS-PTLD incidence is increasing. OBJECTIVE: To describe the characteristics of PCNS-PTLDpatients requiring neurosurgical intervention. METHODS: From 2000 to 2011, 10 patients with prior SOT underwent biopsy for evaluation of brain lesions and were diagnosed with PCNS-PTLD. Data collected included imaging characteristics, pathology, treatments administered, and survival outcomes. RESULTS: All patients had kidney transplantation, and 3 had concurrent pancreas transplantation. Median age at diagnosis was 49 years, with a median of 4.5 years from SOT to diagnosis (range, 1.8-11.4 years). Presenting symptoms most often included focal neurological deficits (n = 6), although several patients had nonspecific symptoms of headache and altered mental status. Brain lesions were generally multiple (n = 7), supratentorial (n = 8), and lobar or periventricular in distribution with ring enhancement. Diagnosis was established by stereotactic (n = 4) and open surgical (n = 6) biopsy. Treatments most frequently administered included reduction of immunosuppression (n = 10), dexamethasone (n = 10), rituximab (n = 8), high-dose methotrexate (n = 3), and whole-brain radiotherapy (n = 6). Six patients remain alive without PCNS-PTLD relapse, including 4 patients who have sustained remissions beyond 2 years from diagnosis of PCNS-PTLD. Of 4 observed deaths, 1 was related to progressive PCNS-PTLD. CONCLUSION:PCNS-PTLD must be considered in the differential diagnosis of any patient with prior SOT presenting with an intracranial lesion. Histological diagnosis with brain biopsy is imperative, given the risk for opportunistic infections that may have similar imaging findings and presentation. Prognosis is variable, although long-term survival has been reported.
Authors: Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: D Gallardo; C Ferrà; J J Berlanga; E D Banda; C Ponce; A Salar; E Alonso; I Espanñol; C Riu; A Grañena Journal: Bone Marrow Transplant Date: 1996-12 Impact factor: 5.483
Authors: Renaud Snanoudj; Antoine Durrbach; Véronique Leblond; Sophie Caillard; Bruno Hurault De Ligny; Christian Noel; Eric Rondeau; Bruno Moulin; Marie-France Mamzer-Bruneel; Catherine Lacroix; Bernard Charpentier Journal: Transplantation Date: 2003-09-27 Impact factor: 4.939
Authors: Amilcar A Castellano-Sanchez; Shiyong Li; Jiang Qian; Anand Lagoo; Edward Weir; Daniel J Brat Journal: Am J Clin Pathol Date: 2004-02 Impact factor: 2.493
Authors: James P Dugan; Bradley M Haverkos; Lynda Villagomez; Ludmila K Martin; Mark Lustberg; John Patton; Marisa Martin; Ying Huang; Gerard Nuovo; Fengting Yan; Robert Cavaliere; Joyce Fingeroth; Shannon C Kenney; Richard F Ambinder; Gerard Lozanski; Pierluigi Porcu; Michael A Caligiuri; Robert A Baiocchi Journal: Clin Cancer Res Date: 2018-04-09 Impact factor: 12.531
Authors: Antonio José da Rocha; Bruno Vasconcelos Sobreira Guedes; Talita Maira Bueno da Silveira da Rocha; Antonio Carlos Martins Maia Junior; Carlos Sérgio Chiattone Journal: Rev Bras Hematol Hemoter Date: 2015-12-31
Authors: Mohamed Ridha; Dylan G Jones; David P Lerner; Michal Vytopil; Barbara Voetsch; Joseph D Burns; Anil Ramineni; Pooja Raibagkar Journal: Virol J Date: 2021-08-06 Impact factor: 4.099